Acelyrin said a contract research organization conducting studies of its lead experimental drug had made “clinical trial execution errors” and it was conducting an audit of the work, a setback that’s likely to cost the biotech time and money.
Monday afternoon’s announcement is bitter news for the company, which went public in May and raised $540 million, only to see its stock crater after the drug, an IL-17A inhibitor named izokibep, failed in a trial of patients with hidradenitis suppurativa earlier this fall.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.